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•KRIT1 over-expression prevents forced up-regulation of c-Jun induced by oxidative stimuli. 
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SUMMARY 
Loss-of-function mutations of the KRIT1 gene (CCM1) have been associated with the pathogenesis 
of Cerebral Cavernous Malformations (CCM), a major cerebrovascular disease. 
However, KRIT1 functions and CCM pathogenetic mechanisms remain incompletely understood. 
Indeed, recent experiments in animal models have clearly demonstrated that the homozygous loss 
of KRIT1 is not sufficient to induce CCM lesions, suggesting that additional factors are necessary 
to cause CCM disease. 
Previously, we found that KRIT1 is involved in the maintenance of the intracellular reactive oxygen 
species (ROS) homeostasis to prevent ROS-induced cellular dysfunctions, including a reduced 
ability to maintain a quiescent state. 
Here, we show that KRIT1 loss-of-function leads to enhanced expression and phosphorylation of 
the redox-sensitive transcription factor c-Jun, as well as induction of its downstream target COX-2, 
both in cellular models and human CCM tissues. Furthermore, we demonstrate that c-Jun up-
regulation can be reversed by either KRIT1 re-expression or ROS scavenging, whereas KRIT1 
over-expression prevents forced up-regulation of c-Jun induced by oxidative stimuli. Taken 
together with the reported role of c-Jun in vascular dysfunctions triggered by oxidative stress, our 
findings shed new light into the molecular mechanisms underlying KRIT1 function and CCM 
pathogenesis. 
INTRODUCTION 
 
Cerebral Cavernous Malformation (CCM) is a major cerebrovascular disease with a prevalence of 
0.3%-0.5% in the general population. It is characterized by closely clustered, abnormally dilated 
and leaky capillary channels (caverns) surrounded by a thick, segmental layered basal membrane, 
and may cause serious clinical symptoms, including recurrent headaches, neurological deficits, 
seizures, stroke, and fatal intracerebral haemorrhage [1]. However, only approximately 30% of 
people with CCM lesions will eventually develop clinical symptoms, which usually occurs between 
the 2nd and 5th decades of life. 
Although advances have been made toward understanding the natural history and molecular basis of 
CCM disease, a complete understanding of the pathogenic mechanisms is still a research challenge 
for defining pharmacological therapies and prognostic factors [1-4]. Indeed, to date there are not 
direct therapeutic approaches for the CCM disease, besides the surgical removal of accessible 
lesions in patients with recurrent haemorrhage or intractable seizures. In particular, novel 
pharmacological strategies are required for preventing the de novo formation of CCM lesions in 
susceptible individuals and the progression of the disease. 
CCM is a disease of proven genetic origin (OMIM 116860) that may arise sporadically or be 
inherited as an autosomal dominant condition with incomplete penetrance and variable expressivity. 
Sporadic cases usually present with a single lesion on cerebral MRI, whereas the familial form 
(fCCM) is characterized by the presence of multiple and evolutive lesions. 
Genetic studies have so far identified three genes whose mutation causes CCM: KRIT1 (CCM1), 
MGC4607 (CCM2) and PDCD10 (CCM3) [5]. Comprehensive studies in cellular and animal 
models have revealed a major role for these genes in blood vessel formation and quiescence 
maintenance, showing a causal link between their loss-of-function mutations and the 
hyperactivation of the RhoA GTPase, which destabilizes endothelial barrier function leading to 
increased vascular permeability [6-8], and suggesting a potential therapy for CCM based on RhoA 
signalling inhibitors, including statins and fasudil [6, 9, 10]. However, whereas the mechanisms 
underlying Rho activation in CCM lesions have yet to be clearly defined, the mechanisms of CCM 
pathogenesis remain incompletely understood and still fundamental challenges for basic and 
translational research [2, 3]. In fact, recent experiments in conditional knockout mouse models have 
clearly demonstrated that the homozygous loss of CCM genes is not sufficient to induce CCM 
lesions, suggesting that additional factors, possibly specific for the neurovascular 
microenvironment, are necessary to cause CCM disease [11]. Deeper insights into the mechanisms 
by which CCM proteins affect vascular functions are therefore urgently needed to ultimately 
provide better treatment options [3]. 
Previously, we found that KRIT1 is involved in the maintenance of the intracellular reactive oxygen 
species (ROS) homeostasis to prevent ROS-mediated cellular dysfunctions via an antioxidant 
pathway involving SOD2, the major cellular antioxidant enzyme, and the transcriptional factor 
FoxO1, a master regulator of cell responses to oxidative stress and a modulator of SOD2 levels. 
Moreover, we demonstrated that the role of KRIT1 in preventing the accumulation of intracellular 
ROS facilitates the down-regulation of Cyclin D1 expression required for cell transition from 
proliferative growth to quiescence [12]. 
To test whether the inverse relationship between KRIT1 and ROS levels could affect sensitive 
intracellular targets involved in the control of important biological functions, including vascular 
permeability and angiogenesis, we analyzed gene regulatory proteins known to be target of 
oxidative stimuli as well as involved in the modulation of endothelial barrier function, including c-
Jun, a major redox-sensitive component of the transcription factor Activator Protein 1 (AP-1) that 
mediates endothelial cell gene responses to oxidants [13, 14]. Indeed, whereas there is clear 
evidence that ROS can act as intracellular second messengers that trigger c-Jun expression and 
activity [13, 15-19], it is known that enhanced ROS levels and c-Jun activation have a critical role 
in the induction of endothelial dysfunction and vascular permeability [17, 20-26]. 
The experimental outcomes showed that KRIT1 loss-of-function is associated with the up-
regulation of c-Jun both in cellular models and human CCM tissue samples. Conversely, either 
KRIT1 re-expression or ROS scavenging reversed the up-regulation of c-Jun induced by KRIT1 
loss. Furthermore, c-Jun up-regulation was correlated with the induction of COX-2, a c-Jun 
downstream target involved in oxidative stress, inflammatory and angiogenic responses [27-29], 
whereas KRIT1 over-expression prevented forced up-regulation of c-Jun induced by exogenous 
oxidative stimuli. 
Taken together, these results demonstrate that KRIT1 controls c-Jun expression through a 
mechanism involving the modulation of ROS homeostasis, suggesting that KRIT1 function may 
exert a protective role in CCM pathogenesis by preventing c-Jun-dependent induction of endothelial 
dysfunction and vascular permeability triggered by oxidative insults. 
MATERIAL AND METHODS 
 
Cell culture, transfection and gene silencing 
KRIT1
-/-
 and KRIT1
+/+
 Mouse Embryonic Fibroblast (MEF) cell lines were established from 
KRIT1
-/-
 and KRIT1
+/+
 E8.5 mouse embryos, respectively, whereas KRIT1 9/6 MEF were obtained 
by infecting KRIT1
-/-
 cells with a lentiviral vector encoding KRIT1 [12]. MEF and HeLa cells were 
cultured at 37°C and 5% CO2 in DMEM supplemented with 10% FCS, 2 mM glutamine and 100 
U/ml penicillin/streptomycin. Human Umbilical Vein Endothelial cells (HUVEC) were cultivated 
in M199 supplemented with 10% FCS, heparin and bovine brain extract (BBE) and maintained at 
37°C and 5% CO2. 
HeLa cells were transiently transfected with pEGFP-KRIT1A construct or pEGFP empty vector as 
control with FuGENE 6 Transfection Reagent (Roche) according to the manufacturer's instructions. 
At 48 h after transfection, cells were used for Western blotting analysis [30].  
The expression of KRIT1 in HeLa cells was silenced by the RNA interference (RNAi) technology 
using two distinct short interfering double stranded RNA oligomers (siRNAs), Silencer® Validated 
#15655 (siK655) and #15469 (siK469) siRNAs (Ambion), corresponding to exon 12 and exon 9 
sequences (GenBank accession n° NM_194455), respectively. The BLOCK-iT
™
 Alexa Fluor
®
 Red 
Fluorescent Oligo (Invitrogen) was used for determination of efficiency of siRNA transfection as 
well as RNAi negative control along with the Silencer® Negative Control #1 siRNA (Ambion). 
Cells were reverse transfected with 30 nM KRIT1-specific or Negative Control siRNAs using the 
Amaxa
®
 HUVEC Nucleofector
®
 Kit and electroporation device (Lonza) according to the optimized 
manufacturer’s reverse transfection protocol. Briefly, cells were harvested by trypsinization and cell 
density was determined using the Countess
™
 automated cell counter (Invitrogen). 5x10
5
 cells per 
sample were pelleted, resuspended in 100 µl of supplemented HUVEC Nucleofector
®
 solution, 
combined with the appropriate dilution of siRNAs, electroporated using the U-001 Nucleofector
®
 
program, and seeded in 6-well plates containing complete culture medium. 48-72 hours post-
transfection, cells were lysed and analyzed by real-time quantitative PCR (RT-qPCR) and Western 
blotting. 
 
Real-Time quantitative PCR 
DNA-free RNA was obtained by purification from cell monolayers using the PureLink RNA Mini 
Kit and DNase I treatment (Invitrogen), and used for cDNA synthesis with the High-Capacity 
cDNA Reverse Transcription Kit (Invitrogen) according to the manufacturer’s instructions. To 
quantify transcript expression levels, an optimal TaqMan
®
 real-time PCR assay was designed for 
each target transcript using the ProbeFinder software (version 2.45) of the Universal Probe Library 
from Roche. TaqMan
®
 gene expression assays were performed in triplicate on MicroAmp
®
 96-well 
optical plates using a 7300 Real Time PCR System (Applied Biosystems). Reactions were carried 
out in 25 μl, containing 8 μl diluted (1:10) cDNA, 12.5 μl 2× qPCR Master Mix (Invitrogen), 0.2 μl 
each primer (20 μM) (Sigma), 0.2 μl Probe (10 μM) (Roche), and 3.9 μl H2O, using the following 
parameters: 50°C for 2 min, 95°C for 2 min, and 45 cycles of 90°C for 15 sec and 60°C for 30 sec. 
The amounts of the target gene expressed in a sample were normalized to the amounts of internal 
normalization controls, including the endogenous 'house-keeping' 18S rRNA and GAPDH 
(glyceraldehyde 3-phosphate dehydrogenase) transcripts. All TaqMan PCR data were collected 
using the Sequence Detector Software (SDS v1.3.1, Applied Biosystems). 
 
Western blotting analysis 
Cells grown in complete culture medium were either mock-treated or treated with either hydrogen 
peroxide (H2O2) (0.1 mM) or the ROS scavenger N-acetylcysteine (NAC) (20 mM) in complete 
medium at 37°C for different time periods. Cells were then lysed and total cell lysates were 
analyzed by Western blotting as previously described [31]. Briefly, cell lysates containing equal 
amounts of total proteins (~50µg) were separated by either 10% or 12% SDS-PAGE and 
electroblotted onto Hybond-C transfer membrane (Amersham). The blots were blocked with 5% 
BSA in Tris-buffered saline (TBS) containing 0.1% Tween 20 for 1 hour at 42°C, incubated with 
appropriate dilutions of primary antibodies overnight at 4°C and subsequently with HRP-
conjugated secondary antibodies for 2 hours at room temperature (RT). Proteins were then 
visualized by an enhanced chemiluminescence (ECL) detection system (Millipore). 
The following antibodies were used: rabbit polyclonal antibodies (pAb) against KRIT1 (K2 pAb, 
Goitre et al., 2010), c-Jun (H-79:sc-1694, Santa Cruz Biotechnology), JNK (sc-571, Santa Cruz 
Biotechnology), GFP (G1544, Sigma); mouse monoclonal antibodies (mAb) against alpha tubulin 
(T5168, Sigma), phospho-c-Jun (KM-1:sc-822, Santa Cruz Biotechnology), phospho-JNK (sc-6254, 
Santa Cruz Biotechnology), COX-2 (610203, BD Transduction Laboratories™), Vinculin (Retta et 
al., 1996). Primary antibodies were detected using affinity purified HRP-conjugated secondary 
antibodies (Sigma). 
In order to compare the density of protein bands of interest and test for significant differences 
between samples in Western blotting experiments, blots were scanned and quantified using ImageJ 
(http://rsb.info.nih.gov/ij/index.html). Band optical density values (mean ± s.d.) were expressed as 
relative protein level units and plotted in representative histograms showed in figures. 
 
Fluorescence microscopy 
For immunofluorescence microscopy analyses, cells were fixed in 3,7% paraformaldehyde for 15 
min, permeabilized with 0.5% Triton X-100 in TBS for 1 min, incubated with 1% BSA in TBS for 
1 h, and stained with primary antibodies and Alexa Fluor® 488 (Invitrogen) secondary antibodies 
for 1 h each at RT. Cells were then counterstained with a blue fluorescent nuclear dye (DAPI) and 
mounted on microscope slides with ProLongH Gold antifade reagent (Molecular Probes, 
Invitrogen) before imaging. Confocal microscopy imaging was performed on a Leica TCS_SP5 
confocal microscope (Leica Microsystems). Instrument parameters for sequential image acquisition, 
including pinhole diameter, laser intensity, exposure time, PMT gain and offset, were set and held 
constant to minimize autofluorescence and for comparison between samples. 
 
Immunohistochemistry 
Histological samples of surgically resected CCM specimens fixed with Carnoy’s fluid 
(methanol:chloroform:acetic acid, 6:3:1) and embedded in paraffin were retrieved from files of the 
Surgical Pathology Unit of Turin's Pediatric Hospital (OIRM - Ospedale Infantile Regina 
Margherita). At the time of neurosurgery an informed consent was asked by neurosurgeons to 
patients (or parents or legal representatives if minors) for genetic analysis of the known CCM 
genes, including CCM1 (KRIT1), and for scientific use of residual materials according to 
Institutional Rules defined by OIRM Ethic Committee. 
Specifically, histological samples of two surgically resected CCM specimens from distinct KRIT1 
loss-of-function mutation carriers were available, including carriers of either a frameshift 
(c.1254delA, 419fs436X) or aberrant splicing (c.1255-4delGTA) mutation. 
Histological serial sections (4 µm thick) of paraffin-embedded CCM specimens were obtained and 
processed by a two-step immunohistochemical staining technique (DAKO EnVision™+ System, 
HRP). Briefly, histological sections were deparaffinized, rehydrated, and subjected to three cycles 
of 5 minutes at boiling temperature in Citrate Buffer (0.01 M pH 6.0) for antigen retrieval. 
Endogenous peroxidase activity was blocked by incubation with hydrogen peroxide (H2O2) 0.3% in 
methanol for 15 minutes, and non-specific binding was prevented by blocking with normal goat 
serum (ab7481, Abcam). Thereafter, the sections were incubated with either rabbit polyclonal or 
mouse monoclonal primary antibodies, including a pAb for c-Jun (H-79:sc-1694, Santa Cruz 
Biotechnology) and mAbs for phospho-c-Jun (KM-1:sc-822, Santa Cruz Biotechnology) and COX-
2 (610203, BD Transduction Laboratories), diluted 1:200 in PBS 0,01 M containing 0,1% BSA and 
0,01% sodium azide, or negative control reagent, followed by incubation with an HRP labelled 
polymer conjugated to secondary antibodies, using two sequential 30-minute incubations at room 
temperature (RT). Labelling was then visualized by a 5-10 minute incubation with 3,3’-
diaminobenzidine (DAB)+H2O2 substrate-chromogen, which results in a brown-coloured 
precipitate at the antigen site. The sections were subsequently counterstained with haematoxylin. 
 
Statistics 
Data are expressed as mean ± s.d.. Statistical analyses were performed by one-way analysis of 
variance (ANOVA) followed by Bonferroni correction. P < 0.05 was used as the threshold for 
statistically significant differences. The results showed in figures are representative of at least three 
independent experiments. 
 
RESULTS 
 
KRIT1 regulates c-Jun expression 
Previously we showed that KRIT1 loss is associated with an increase in intracellular ROS levels as 
well as with ROS-mediated cellular dysfunctions, including a reduced ability to maintain a 
quiescent state [12]. 
A growing body of evidence suggests that the cellular response to unbalanced ROS overproduction 
and detoxification is primarily regulated at the level of transcription. Indeed, posttranslational 
modification of redox-sensitive transcription factors may provide a mechanism by which cells sense 
these redox changes [18]. 
To further characterize the functional significance of KRIT1 involvement in the maintenance of the 
intracellular ROS homeostasis, we analyzed the effects of KRIT1 loss on the expression of c-Jun, a 
redox-sensitive transcription factor known to be involved in the modulation of endothelial barrier 
function and angiogenesis [13, 18, 21, 22, 25, 26]. 
As a first approach, we performed real-time quantitative PCR (RT-qPCR) and Western blotting 
analysis of c-Jun mRNA and protein expression levels in KRIT1
-/-
 (K
-/-
) and wild-type (K
+/+
) mouse 
embryonic fibroblasts (MEF), established from KRIT1
-/-
 and KRIT1
+/+
 E8.5 mouse embryos 
respectively, as well as in KRIT1
-/-
 MEFs re-expressing KRIT1 (K9/6) [12]. 
The outcomes of these experiments showed that c-Jun expression was significantly higher in 
KRIT1
-/-
 (K
-/-
) than in wild-type (K
+/+
) and KRIT1
-/-
 MEFs re-expressing KRIT1 (K9/6) both at 
mRNA (Fig. 1A) and protein (Fig. 1B) levels, suggesting that KRIT1 loss leads to c-Jun up-
regulation. 
To evaluate whether this effect was associated with c-Jun activating phosphorylation and efficient 
import into the nucleus, we examined phospho-c-Jun levels and subcellular localization. Western 
blotting analysis of whole cell extracts with a mAb specific for the active, phosphorylated form of 
c-Jun (at Ser-63 and Ser-73) (P-c-Jun) showed that phospho-c-Jun levels were always correlated 
with total c-Jun levels, being significantly higher in K
-/-
 than in K
+/+
 and K9/6 MEF cells (Fig. 1B, 
P-c-Jun, and 1C). Furthermore, fluorescence microscopy analysis of K
-/-
 and K9/6 MEF cells with 
the anti-phospho-c-Jun mAb confirmed that phospho-c-Jun levels were higher in K
-/-
 than in K9/6 
MEF cells (Fig. 1D, panels a,b), and showed a correct nuclear localization in cells lacking KRIT1 
(Fig. 1D, panels a,c,e). 
Remarkably, an inverse correlation between KRIT1 and c-Jun expression/phosphorylation levels 
was also observed (Fig. 1A-C), suggesting that KRIT1 plays a role in controlling c-Jun expression 
and activity. 
To further assess this evidence, we used other cell types, including epithelial and endothelial cells, 
and modulated the expression of KRIT1 by two additional and complementary approaches, such as 
knockdown and overexpression approaches. 
KRIT1 knockdown was performed in HeLa (Fig. 2A-E) and HUVEC (Fig. 2F) cells using two 
distinct KRIT1-specific siRNA (siK655 and siK469), which induced a significant decrease of 
KRIT1 expression at both mRNA (Fig. 2A) and protein (Fig. 2C-F) levels. Notably, as detected by 
real time RT-PCR (RT-qPCR) and Western blotting assays, the siRNA-mediated knockdown of 
KRIT1 resulted in a significant up-regulation of c-Jun mRNA (Fig. 2B) and protein (Fig. 2C-F) 
expression levels, supporting the evidence that KRIT1 down-regulation causes the up-regulation of 
c-Jun. Notably, the up-regulated levels of c-Jun were again correlated with corresponding enhanced 
levels of the active, phosphorylated form of c-Jun (Fig. 2D). 
Taken together, the KRIT1 knockout and knockdown approaches demonstrate that KRIT1 
loss/down-regulation is associated with a significant up-regulation of c-Jun/phospho-c-Jun levels. 
Conversely, the forced re-expression of KRIT1 in KRIT1
-/-
 MEF cells to levels higher than wild-
type cells (Fig. 1B, compare KRIT1 levels in K9/6 and K
+/+
 MEFs) caused a significant down-
regulation of c-Jun/phospho-c-Jun expression both at protein (Fig. 1B) and mRNA (Fig. 1A) levels, 
suggesting a dose-dependent inverse relationship between KRIT1 and c-Jun levels. 
To provide further support to the existence of this inverse relationship, we induced KRIT1 
overexpression in HeLa cells via transient transfection with a GFP-tagged KRIT1 construct [30]. 
Consistent with the outcomes of the alternative KRIT1 knockout and knockdown approaches 
described above, this third complementary approach showed that the forced up-regulation of KRIT1 
leads to a strong down-regulation of c-Jun protein levels (Fig. 3A,B), clearly demonstrating that 
KRIT1 is able to keep c-Jun expression under strict control. 
All together, these results suggest that KRIT1 plays a dose-dependent role in limiting c-Jun 
expression and activity. 
 
ROS scavenging reverses the up-regulation of c-Jun expression/phosphorylation caused by 
KRIT1 loss 
There is clear evidence that ROS trigger c-Jun activity by inducing both c-Jun expression and 
activating phosphorylation [13, 18]. 
To test whether the c-Jun up-regulation observed in KRIT1
-/-
 MEF cells was attributable to the 
previously reported KRIT1 loss-dependent enhanced steady-state levels of intracellular ROS [12], 
we analyzed both c-Jun expression and phosphorylation in KRIT1
-/-
 (K
-/-
), wild-type (K
+/+
) and 
KRIT1 overexpressing (K9/6) MEF cells after cell treatment with the antioxidant N-acetylcysteine 
(NAC), which was previously demonstrated to be effective in reducing the levels of ROS in K
-/-
 
cells closely near to the levels of K9/6 cells and rescuing KRIT1 loss-dependent ROS-mediated 
molecular and cellular dysfunctions, including the up-regulation of Cyclin D1 and the reduced cell 
ability to maintain a quiescent state [12]. The outcomes of these experiments showed that treatment 
of KRIT1
-/-
 cells with NAC led to a significant reduction of both c-Jun expression and 
phosphorylation as compared with relative levels in untreated cells (Fig. 4A-D), indicating that the 
enhanced c-Jun expression and phosphorylation associated with KRIT1 loss is a redox-sensitive 
phenomenon. Furthermore, the reduced levels of c-Jun expression and phosphorylation observed in 
KRIT1
-/-
 cells upon NAC treatment were close to levels observed in untreated wild-type cells (Fig. 
4A,B), suggesting that the enhanced c-Jun expression and phosphorylation associated with KRIT1 
loss may indeed be largely reversed by antioxidants. 
 
KRIT1 overexpression prevents forced up-regulation of c-Jun induced by oxidative stimuli 
There is strong evidence that oxidative stress due to either exogenous oxidants or the unbalanced 
overproduction and detoxification of intracellular ROS, including superoxide anion (O2
∙-
) and 
hydrogen peroxide (H2O2), leads to an increase in c-Jun expression and transcriptional activity [15, 
16, 18, 19, 32-35]. 
On the other hand, we showed previously that KRIT1 prevents oxidative stress-mediated cellular 
dysfunctions by limiting the accumulation of intracellular ROS in a dose-dependent manner [36]. 
In this light, we hypothesized that the expression of KRIT1 could prevent the increase of c-Jun 
expression levels triggered by exogenous oxidative stimuli. To test this hypothesis, c-Jun protein 
levels were assayed in KRIT1
-/-
 (K
-/-
), wild-type (K
+/+
) and KRIT1 overexpressing (K9/6) MEF 
cells either mock-treated or treated with H2O2. 
Consistent with the above reported finding that KRIT1 dose-dependently regulates c-Jun steady-
state levels, these resulted inversely proportional to KRIT1 expression levels in untreated MEFs 
(Fig. 5A, lanes 1,3,5, and 5B,C). However, while c-Jun was significantly up-regulated upon H2O2 
treatment in both K
-/-
 and K
+/+
 MEFs, confirming that oxidative stimuli induce c-Jun up-regulation 
[18], this did not occur in K9/6 MEFs (Fig. 5A, lanes 2,4,6, and 5B), indicating that KRIT1 
overexpression prevents forced up-regulation of c-Jun induced by oxidative stimuli, and further 
suggesting that KRIT1 plays a role in protecting cells against exogenous oxidative insults. 
Furthermore, whereas previous FACS analysis demonstrated that KRIT1 overexpression prevents 
ROS enhancement in response to cell treatment with either inorganic or organic oxidants, including 
H2O2 and tert-butyl hydroperoxide [12], Western blotting assays showed that phospho-c-Jun levels 
were again correlated with total c-Jun levels (Fig. 5A,B,D,E),. Intriguingly, a slight down-
regulation of KRIT1 protein levels was also observed upon H2O2 treatment in both wild-type (K
+/+
) 
and KRIT1 overexpressing (K9/6) MEF cells (Fig. 5A,C,D), which deserve future investigation. 
 
c-Jun expression/phosphorylation is enhanced in CCM lesions from KRIT1 loss-of-function 
mutation carriers 
CCM lesions are characterized by altered blood-brain barrier function and increased vessel 
permeability due to the weakening of endothelial cell-cell junctions [6-8]. Interestingly, there is 
clear evidence that c-Jun up-regulation is linked to the induction of endothelial dysfunction and 
vascular permeability [21, 22, 25, 26]. In this light, we hypothesized that the KRIT1 loss-of-
function-dependent up-regulation of c-Jun expression and phosphorylation observed in cellular 
models could also occur in vivo. To address this hypothesis, we performed immunohistochemical 
analysis of c-Jun expression and phosphorylation levels in surgically resected human CCM 
specimens from patients carrying a KRIT1 loss-of-function mutation. Notably, the results of these 
experiments showed a significant positive staining for both total c-Jun and phospho-c-Jun in 
endothelial cells lining the lumen of CCM lesions as compared with peri-lesion normal vessels, 
with up to 90% of positive cells in the most abnormally dilated vessels (Fig. 6), clearly 
demonstrating that the up-regulation of c-Jun caused by KRIT1 loss-of-function occurs also in vivo, 
and suggesting a potential relationship with CCM disease. 
 
KRIT1 loss-of-function induces a ROS-dependent activation of JNK 
There is evidence that the role of oxidants and oxidative stress in enhancing c-Jun expression and 
transcriptional activity is mediated, at least in part, by the c-Jun NH2-terminal kinase (JNK), a 
major upstream regulator of c-Jun. Indeed, oxidative stress induces phosphorylation and activation 
of JNK, facilitating its entry into the nucleus. Nuclear JNK phosphorylates c-Jun at serines 63 and 
73 regulatory sites within the N-terminal transactivation domain, enhancing its transcriptional 
activities [13, 18].  
To test whether c-Jun up-regulation induced by KRIT1 loss-of-function was correlated with the 
activation of JNK, we performed Western blotting analysis of cell extracts from KRIT1
-/-
 (K
-/-
) and 
KRIT1 overexpressing (K9/6) MEF cells using a monoclonal antibody specific for the active, 
phosphorylated form of JNK (at Thr 183 and Tyr 185) (P-JNK). The outcomes of these experiments 
showed that phospho-JNK levels were significantly higher in K
-/-
 than in K9/6 MEF cells (Fig. 7A, 
P-JNK), thus paralleling the enhanced P-c-Jun levels (Fig. 7A, P-c-Jun, and previous figures); in 
contrast, the levels of total JNK were not significantly varied (Fig. 7A, JNK). 
To test whether the activating phosphorylation of JNK observed in KRIT1
-/-
 MEF cells was ROS-
dependent, we then analyzed P-JNK levels upon cell treatment with the antioxidant NAC. Indeed, 
cell treatment with NAC was effective in reducing both JNK and c-Jun phosphorylation (Fig. 7B), 
indicating that KRIT1 loss-of-function induces a ROS-dependent activation of JNK, and suggesting 
that this activation plays an upstream regulatory role in mediating the ROS-dependent up-regulation 
of c-Jun. However, cell treatment with an inhibitor of JNK (SP600125) rescued only partially the 
ROS-dependent up-regulation of c-Jun induced by KRIT1 loss (data not shown), suggesting that 
additional regulatory factors acting upstream of c-Jun are likely involved. 
 
KRIT1 loss-of-function induces downstream targets of c-Jun 
Activation of c-Jun promotes induction of both proliferative and proinflammatory gene products. 
Notably, we previously found that KRIT1 loss-of-function leads to a ROS-mediated up-regulation 
of Cyclin D1 [12, 37], a major c-Jun target gene involved in cell cycle progression through the G1 
phase [12, 37], suggesting a plausible involvement of c-Jun in the reduced cell ability to maintain a 
quiescent state caused by KRIT1 loss. To further extend the potential functional significance of the 
inverse relationship between KRIT1 expression and c-Jun expression and its oxidative stress-
induced activation, we then tested c-Jun target genes known to be involved in proinflammatory 
responses, including cycloxygenase-2 (COX-2), a major oxidative stress biomarker and 
inflammatory mediator involved in angiogenesis and vascular dysfunction [27-29]. 
As detected by real time RT-PCR (RT-qPCR) and Western blotting assays, COX-2 expression was 
significantly higher in KRIT1
-/-
 (K
-/-
) than in wild-type (K
+/+
) and KRIT1
-/-
 MEFs re-expressing 
KRIT1 (K9/6) both at mRNA (Fig. 8A) and protein (Fig. 8B) levels, suggesting that KRIT1 loss 
leads to COX-2 up-regulation. Moreover, COX-2 protein levels were directly correlated with P-c-
Jun levels (Fig. 8B), suggesting a potential relationship. Furthermore, immunohistochemical 
analysis of COX-2 expression in surgically resected human CCM specimens from patients carrying 
a KRIT1 loss-of-function mutation showed a significant positive staining in endothelial cells lining 
the lumen of CCM lesions, with most cells showing a prevalent COX-2 perinuclear/nuclear 
localization (Fig. 8C), suggesting that the up-regulation of COX-2 caused by KRIT1 loss-of-
function may occur also in vivo, and pointing to a potential relationship with CCM disease. 
While further studies based on c-Jun dominant negative inhibition and RNAi-mediated knockdown 
are required to verify the putative direct relationship between the KRIT1 loss-dependent up-
regulation of c-Jun and its target genes, including but not limited to Cyclin D1 and COX2, the 
findings that KRIT1 plays a role in regulating distinct proteins involved in oxidative stress 
responses open novel avenues for future investigations aimed at better defining the molecular 
mechanisms of CCM pathogenesis. 
DISCUSSION 
 
KRIT1 loss-of-function mutations have been clearly associated with the pathogenesis of Cerebral 
Cavernous Malformations (CCM), a major cerebrovascular disease characterized by abnormally 
enlarged and leaky capillaries that predispose to seizures, focal neurological deficits, and fatal 
intracerebral haemorrhage. In particular, comprehensive analysis of the KRIT1 gene in CCM 
patients has suggested that KRIT1 functions need to be severely impaired for pathogenesis, whereas 
studies in cellular and animal models have demonstrated that KRIT1 deficiency leads to the major 
molecular and cellular hallmarks of CCM disease, including destabilization of endothelial cell-cell 
junctions, reduced cells’ ability to maintain a quiescent state, and increased vascular permeability 
and angiogenic potential [6, 12, 38-42]. However, recent experiments in animal models have shown 
that loss-of function of CCM genes, including KRIT1 (CCM1), is not sufficient to induce CCM 
lesions, suggesting that additional triggers occurring locally at neurovascular units, including 
microenvironmental stress factors and brain injuries, are necessary to promote the onset and 
progression of CCM disease [3, 11]. 
Among the microenvironmental stress events that might account for a sort of environmental second 
hit, triggering CCM lesion formation in sensitive vascular areas of CCM mutation carriers, there is 
oxidative stress. This may occur as a consequence of an endogenous imbalance between the 
production of reactive oxygen species (ROS) and the ability of cellular antioxidant mechanisms to 
readily prevent excessive ROS accumulation maintaining a physiological equilibrium, as well as by 
exogenous oxidative insults, including cell exposure to xenobiotics or ionizing radiations [36]. 
Furthermore, pro-oxidant factors may be released locally following inflammatory responses, 
impaired neurovascular coupling, and ischemia-reperfusion events [20]. Remarkably, there is now a 
wealth of evidence indicating that oxidative stress is indeed a major cause of vascular remodelling 
and neurovascular unit dysfunction associated with cerebrovascular diseases [20, 23, 43]. In 
particular, oxidative stress has been clearly implicated in all the major molecular and cellular 
dysfunctions related to CCM diseases, including destabilization of endothelial cell-cell junctions, 
reduced cells’ ability to maintain a quiescent state, and increased vascular permeability and 
angiogenic activity [24, 36, 44], suggesting that it might represent a significant additive factor 
involved in the initiation and progression of CCM disease. 
Consistently, we previously reported that KRIT1 is involved in the maintenance of intracellular 
ROS homeostasis to prevent ROS-mediated cell dysfunctions through an antioxidant pathway 
involving SOD2, the major cellular antioxidant enzyme, and the transcriptional factor FoxO1, a 
master regulator of cell responses to oxidative stress and a modulator of SOD2 levels, raising the 
hypothesis that CCM lesions may result from an impaired oxidative stress defence in microvascular 
districts of genetically predisposed subjects, and opening new therapeutic perspectives [12, 45]. 
These original results and hypothesis are now further supported and expanded by novel findings 
showing that KRIT1 loss-of-function causes the up-regulation of c-Jun both in cellular models and 
human CCM tissue samples, as well as that this up-regulation can be reversed by either KRIT1 re-
expression or ROS scavenging with antioxidant compounds, including N-acetylcysteine (NAC), 
suggesting that KRIT1 controls c-Jun expression through the regulation of intracellular ROS 
homeostasis. 
c-Jun, a prominent member of the AP-1 transcription family, has been implicated in the regulation 
of a wide range of biological processes including development, differentiation, transformation, and 
apoptosis [14]. It is now clear that c-Jun activity is closely associated with a steady elevation of its 
expression through an autocrine and feed-forward transcriptional mechanism, as well as with the 
phosphorylation of two serine residues, Ser-63 and Ser-73, located within the N-terminal 
transcription activation domain, whereas its effects on cellular responses depend strongly on the 
context of other regulatory influences that the cell is receiving [14]. Both c-Jun expression and 
phosphorylation are highly induced in response to environmental cues, including mitogenic stimuli 
and various stresses [14, 46]. 
According with our findings, there is clear evidence that c-Jun is highly up-regulated in response to 
either oxidants or oxidative stress, and associated with vascular dysfunctions, including vascular 
remodelling and inflammation, and enhanced vascular permeability [13, 15-19, 47]. Conversely, 
there is also evidence that increased cellular glutathione levels by NAC inhibit the expression and 
transcriptional activity of c-Jun triggered by numerous stimuli [18], including the binding of c-Jun 
to the AP-1 element within the VEGF promoter [48]. 
Notably, the finding that KRIT1 high expression levels prevent forced up-regulation of c-Jun 
induced by oxidative stimuli suggests that the dose-dependent inverse relationship between KRIT1 
and c-Jun levels may play an important role in protecting cells against exogenous oxidative insults. 
Accordingly, previously reported findings showed that KRIT1 overexpression prevents ROS 
enhancement in response to cell treatment with either inorganic or organic oxidants, including H2O2 
and tert-butyl hydroperoxide, conferring resistance to exogenous oxidative challenge-induced DNA 
damage and apoptotic response [12]. 
Moreover, our novel findings are reinforced by complementary results showing that KRIT1 loss-of-
function-dependent and redox-sensitive up-regulation of c-Jun correlates with the up-regulation of 
both upstream regulators and downstream targets of c-Jun. In particular, we show that the up-
regulation of c-Jun is accompanied by a redox-sensitive activating phosphorylation of JNK, a major 
c-Jun upstream regulator known to be activated by oxidants and oxidative stress [13, 18]. 
Accordingly and intriguingly, an enhanced phosphorylation of JNK has been previously observed in 
CCM2-depleted cells [6-8], suggesting that it might represent a general consequence of the 
deficiency of any CCM protein. 
Besides JNK, multiple signalling molecules have been proposed as potential upstream regulators for 
ROS induction of c-Jun expression and activity, including extracellular signal-regulated kinases 
(ERKs), p38 mitogen-activated protein kinases (p38MAPK), phospholipase A2 (PLA2), 
arachidonic acid, lipoxygenase (LOX), and protein kinase C (PKC), as well as tyrosine kinases and 
tyrosine and serine/threonine phosphatises [13, 15-19]. Accordingly, cell treatment with an inhibitor 
of JNK (SP600125) rescued only partially the ROS-dependent up-regulation of c-Jun induced by 
KRIT1 loss, suggesting that additional regulatory factors acting upstream of c-Jun are likely 
involved. Further studies based on pharmacologic inhibition and RNAi-mediated knockdown of 
distinct c-Jun upstream regulators are therefore required to gain further insights into the likely 
complex redox-sensitive molecular machinery that links KRIT1 to the ROS-mediated activation of 
c-Jun. 
On the other hand, previous results showed that KRIT1 loss-of-function leads to a ROS-mediated 
up-regulation of Cyclin D1 [12, 37], a major c-Jun target gene involved in cell cycle progression 
[12, 37], suggesting a potential involvement of c-Jun in the reduced cell ability to maintain a 
quiescent state caused by KRIT1 loss [12, 37]. In addition, here we report that the up-regulation of 
c-Jun is paralleled by the induction of COX-2, a major c-Jun target gene [49] as well as a major 
oxidative stress biomarker and inflammatory mediator involved in vascular dysfunction [27-29], 
raising the possibility that KRIT1 loss-of-function might be implicated in synergistic oxidative 
stress and inflammatory responses. Consistently, a close relationship between oxidative stress and 
local inflammation has been clearly established and shown to underlie vascular disease of diverse 
etiology [43, 50]. Furthermore, whereas a recent report shows that mice heterozygous for the 
deletion of the KRIT1 gene (KRIT1
+/-
) exhibit an enhanced sensitivity to inflammatory stimuli [38], 
there is evidence that inflammatory response occurs in CCM lesions [51, 52], supporting a potential 
role for inflammatory processes in the pathogenesis of CCM disease. On the other hand, whereas 
evidence in animal models suggests that neoangiogenic events are necessary to cause CCM disease 
[11], a key molecular link connecting oxidative stress and angiogenesis has been also established, 
with oxidative stress having potential primacy [53]. Indeed, reciprocity of inflammation, oxidative 
stress and neovascularization is emerging as an important mechanism underlying numerous 
biological processes [53], raising the possibility that these mechanisms play key sequential and 
synergistic roles in CCM pathogenesis. 
Consistently, an increased ROS production has been associated with endothelial dysfunction and 
onset of the CCM-related disease Hereditary Hemorrhagic Telangiectasia [54, 55]. 
In this light, the evidence that both the phosphorylated, active form of c-Jun and COX-2 are 
enhanced in endothelial cells lining CCM lesions from KRIT1 loss-of-function mutation carriers 
suggests that the up-regulation of these proteins may actively contribute to the pathogenesis of 
CCM disease by acting synergistically with local microenvironmental factors affecting endothelial 
function and vascular permeability, including locally released oxidative stress, inflammatory and 
angiogenic factors. 
Future focused research is required to address this possibility, as well as to assess whether COX-2 is 
activated as a consequence of the KRIT1 loss-of-function-dependent and ROS-mediated up-
regulation of c-Jun. Indeed, although it is clearly established that c-Jun activation is upstream of 
COX-2 expression, there is also evidence that COX-2 can be induced by other redox-sensitive 
transcription factors, including NF-kB, and may act both upstream and downstream of ROS 
signalling [27-29]. Nonetheless, our findings open a promising novel research avenue and provide a 
useful framework for paving the way toward a better understanding of the molecular events 
underlying the pathogenesis of CCM disease. 
Remarkably and consistent with our finding and hypothesis, c-Jun up-regulation has been linked 
with pathological angiogenesis and microvascular diseases in humans, whereas its inhibition has 
been shown to be effective as a rescue therapy for these diseases [21, 22, 25, 26, 34, 56]. In 
particular, it has been demonstrated that targeting of c-Jun inhibits microvascular endothelial cell 
proliferation, migration, invasion, tubule formation, and endothelial cell production of matrix 
metalloproteinase-2 (MMP-2) in vitro [25, 26], and suppresses VEGF-induced neovascularization, 
MMP-2 production, and vascular permeability and inflammation in vivo [21, 25, 26]. 
In this light, it is noteworthy that an up-regulation of c-Jun downstream targets involved in cell 
cycle progression and extracellular matrix remodelling, including cyclin D1 and MMP2 [25, 37], 
has been previously observed in cellular models of CCM [12] and human CCM lesions [57], 
respectively. On the other hand, our recently reported findings related to a role of TGF-β in CCM 
patients [58] might also be connected to and downstream of deregulation of oxidative stress and c-
Jun activity. Indeed, whereas there is clear evidence that ROS can stimulate the activation of the 
TGF-β pathway with important consequences on cellular functions [59, 60], it has been 
demonstrated that this ROS-mediated regulation is dependent on AP-1 transcriptional activity [60]. 
 
 
 
CONCLUSIONS 
Taken together with the above observations, our experimental results demonstrating that KRIT1 
controls c-Jun expression and phosphorylation through a mechanism involving the modulation of 
ROS homeostasis suggest an important role for ROS and the redox-sensitive transcription factor c-
Jun in CCM pathogenesis, and point to a model mechanism whereby the dose of KRIT1 may be 
relevant in preventing c-Jun-dependent induction of vascular dysfunctions triggered by oxidative 
stress (Fig. 9). 
Importantly, our findings provide also an alternative explanation to the suggested effectiveness of 
fasudil and statins as potential therapy for CCM disease [6, 9, 10]. Indeed, whereas it has been 
demonstrated that the Rho GTPase pathway can be directly activated by ROS [61], there is clear 
evidence that both fasudil and statins exert powerful intracellular antioxidant activities in 
endothelial cells, including the inhibition of superoxide production and the improvement of both 
ROS scavenging and NO bioavailability [62-64]. 
Future progress toward this novel perspective should pave the way for the development of novel, 
safe and effective therapeutic strategies for prevention and treatment of CCM disease. 
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FIGURE LEGENDS 
 
Figure 1. KRIT1 regulates c-Jun expression - KRIT1 knockout and re-expression approach. 
KRIT1
-/-
 (K
-/-
) and wild-type (K
+/+
) MEFs and KRIT1
-/-
 MEFs re-expressing KRIT1 (K9/6) were 
grown to confluence under standard conditions and analyzed by RT-qPCR (A), Western blotting 
(B,C), and immunofluorescence (D) as described in Materials and Methods. 
A) RT-qPCR analysis of c-Jun mRNA expression levels. The amount of each target mRNA 
expressed in a sample was analyzed in triplicate using appropriate TaqMan
®
 gene expression assays 
(Roche), and normalized to the amounts of internal normalization control transcripts (18S rRNA). 
Results are expressed as relative mRNA level units referred to the average value obtained for the 
KRIT1
-/-
 (K
-/-) samples, and represent the mean (± s.d.) of n≥3 independent RT-qPCR experiments. 
***P≤0.001 versus KRIT1-/- (K-/-) cells. Notice that c-Jun mRNA levels are significantly higher in 
K
-/-
 than in K
+/+
 and K9/6 MEFs. 
B) Representative Western blot analysis of the relative c-Jun, phospho-c-Jun, and KRIT1 
expression levels. Tubulin (-Tub) was used as loading control. Notice that both c-Jun and 
phospho-c-Jun levels are significantly higher in K
-/-
 than in K
+/+
 and K9/6 MEFs. An inverse 
correlation between c-Jun/phospho-c-Jun and KRIT1 protein levels is also evident. 
C) Histograms showing quantitative results of Western blot analysis of the relative c-Jun, phospho-
c-Jun, and KRIT1 expression levels. Optical density values are expressed as relative protein level 
units referred to the average value obtained for the KRIT1
-/-
 (K
-/-
) samples, and represent the mean 
(± s.d.) of n≥3 independent Western blot experiments. ***P≤0.001 versus KRIT1-/- (K-/-) cells. 
Notice that differences in phospho-c-Jun levels are correlated with differences in total c-Jun levels. 
D) Confocal microscopy analysis of phospho-c-Jun levels and subcellular localization in K
-/-
 and 
K9/6 MEF cells. Phospho-c-Jun and nuclei were visualized with anti-phospho-c-Jun mAb coupled 
to Alexa Fluor® 488 secondary antibody and DAPI dye, respectively. Notice that phospho-c-Jun is 
correctly localized to the nucleus in cells lacking KRIT1 (K
-/-
) and shows enhanced levels as 
compared to KRIT1 re-expressing cells (K9/6). Scale bar represents 15 μm. 
 
Figure 2. KRIT1 regulates c-Jun expression - KRIT1 down-regulation (siRNA) approach. 
HeLa (A-E) and Human Umbilical Vein Endothelial (HUVEC) cells (F) were mock transfected or 
transfected with either a KRIT1-specific siRNA (siK655 or siK469) or a negative control siRNA 
(siNC). 48 hours post-transfection, cells were lysed and analyzed by RT-qPCR (A-B) and Western 
blotting (C,D,F) to assess c-Jun and KRIT1 mRNA and protein levels, respectively. 18S rRNA and 
Tubulin (-Tub) were used as endogenous controls for RT-qPCR normalization and Western blot 
loading, respectively. Notice that the siRNA-mediated knockdown of KRIT1 results in the up-
regulation of c-Jun and phospho-c-Jun expression levels. Histograms show quantitative results of 
RT-qPCR (A,B) and Western blot (E,F) analysis of the relative c-Jun and KRIT1 mRNA and 
protein expression levels, respectively. mRNA levels (A,B) and optical density values of Western 
blot bands (E,F) are expressed as relative level units referred to the average value obtained for the 
mock transfected cells, and represent the mean (± s.d.) of n=3 independent experiments. 
***P≤0.001 versus mock transfected cells. 
 
Figure 3. KRIT1 regulates c-Jun expression - KRIT1 overexpression approach. 
HeLa cells were mock transfected or transiently transfected with a GFP-tagged KRIT1A construct. 
48 hours post-transfection, cells were lysed and analyzed by Western blotting with anti-c-Jun (c-
Jun) and anti-GFP (GFP-KRIT1 and GFP) antibodies. Tubulin (-Tub) was used as loading control. 
Notice that KRIT1 overexpression in HeLa cells results in the down-regulation of c-Jun protein 
levels. Histograms show quantitative results of Western blot analysis of the relative c-Jun and 
KRIT1 expression levels. Band optical density values are expressed as relative protein level units 
referred to the average value obtained for the mock transfected cells, and represent the mean (± s.d.) 
of n=3 independent Western blot experiments. ***P≤0.001 versus mock transfected cells. 
 
Figure 4. ROS scavenging overcomes the up-regulation of c-Jun expression/phosphorylation 
caused by KRIT1 loss. 
KRIT1
-/-
 (K
-/-
), wild-type (K
+/+
), and Lv-KRIT1 (K9/6) MEFs grown to confluence were either 
mock-treated or treated with the ROS scavenging agent N-acetylcysteine (NAC) (20 mM in 
complete medium) for 120 minutes at 37°C. Cells were then lysed and analyzed by Western 
blotting with either c-Jun (c-Jun) (A) or phospho-c-Jun (P-c-Jun) (B) antibodies. Vinculin was used 
as loading control. Notice that c-Jun expression and phosphorylation levels in KRIT1
-/-
 cells treated 
with the ROS scavenger NAC (K
-/-
 NAC) are significantly reduced as compared with untreated 
KRIT1
-/-
 cells, and close to the levels of untreated wild-type cells (K
+/+
). C) Histograms showing 
quantitative results of Western blot analysis of c-Jun and phospho-c-Jun expression levels. Band 
optical density values are expressed as relative protein level units referred to the average value 
obtained for untreated KRIT1
-/-
 (K
-/-
) cells, and represent the mean (± s.d.) of n=3 independent 
Western blot experiments. **P≤0.01 versus untreated KRIT1-/- (K-/-) cells. 
 
Figure 5. KRIT1 over-expression prevents forced up-regulation of c-Jun induced by oxidative 
stimuli. 
KRIT1
-/-
 (K
-/-
) and wild-type (K
+/+
) MEFs and Lv-KRIT1 (K9/6) grown to confluence were either 
mock-treated or treated with H2O2 (0.1 mM in complete medium) for 60 minutes at 37°C. Cells 
were then lysed and analyzed by Western blotting with anti-c-Jun (c-Jun) and anti-KRIT1 (KRIT1) 
antibodies. Tubulin (-Tub) was used as loading control. Notice that KRIT1 overexpression 
prevents forced up-regulation of c-Jun induced by oxidative stimuli. Histograms show quantitative 
results of Western blot analysis of the relative c-Jun (B), KRIT1 (C), and P-c-Jun expression levels. 
Band optical density values are expressed as relative protein level units referred to the average 
value obtained for untreated KRIT1
-/-
 (K
-/-
) cells, and represent the mean (± s.d.) of n=3 
independent Western blot experiments. ***P≤0.001 versus untreated KRIT1-/- (K-/-) cells. 
 
Figure 6. c-Jun expression and phosphorylation are enhanced in CCM lesions from KRIT1 
loss-of-function mutation carriers. 
Histological sections (4 µm) of paraffin-embedded CCM surgical specimens, deriving from a 
KRIT1 loss-of-function mutation carrier, were processed by a two-step immunohistochemical 
staining technique (DAKO EnVision™+ System, HRP) with c-Jun and phospho-c-Jun antibodies to 
assess c-Jun (A,B) and phospho-c-Jun (C,D) expression in peri-lesion and CCM lesion vessels. 
Notice that many endothelial cells lining the lumen (l) of CCM vessels (B,D) were positive for c-
Jun (B) and phospho-c-Jun (D), while neither c-Jun (A) nor phospho-c-Jun (C) positive staining 
was detected in peri-lesion normal vessels (A,C). Magnification: 20X. 
 
Figure 7. KRIT1 loss-of-function induces a ROS-dependent activation of JNK. 
KRIT1
-/-
 (K
-/-
) and Lv-KRIT1 (K9/6) MEFs grown to confluence were left untreated (A) or either 
mock-treated or treated with the ROS scavenging agent N-acetylcysteine (NAC) (20 mM in 
complete medium) for 120 minutes at 37°C (B). Cells were then lysed and analyzed by Western 
blotting as described in Materials and Methods. 
The phosphorylated JNK and total JNK were probed using anti-phospho-JNK (Thr183/Tyr185) 
antibody and anti-JNK antibody, and compared to the relative P-c-Jun and KRIT1 expression 
levels. Total JNK and Tubulin (-Tub) served as loading controls. 
A) Notice that JNK phosphorylation is significantly higher in K
-/-
 than in K9/6 MEFs and correlated 
with P-c-Jun levels. An inverse correlation between P-JNK and KRIT1 protein levels is also 
evident. 
B) Notice that P-JNK levels in K
-/-
 MEFs treated with the ROS scavenger NAC (K
-/-
 NAC+) are 
significantly reduced as compared with untreated K
-/-
 cells (K
-/-
 NAC-), and close to the levels of 
untreated K9/6 MEFs (K9/6 NAC-). A direct correlation between P-JNK and P-c-Jun and an 
inverse correlation between P-JNK and KRIT1 levels is also evident. 
 
Figure 8. KRIT1 loss-of-function causes the up-regulation of cycloxygenase 2 (COX-2). 
A-B) KRIT1
-/-
 (K
-/-
), wild-type (K
+/+
), and Lv-KRIT1 (K9/6) MEFs were grown to confluence 
under standard conditions and analyzed by RTqPCR (A) and Western blotting (B). 
A) RT-qPCR analysis. COX-2 mRNA expression levels were analyzed in triplicate using 
appropriate TaqMan
®
 gene expression assays (Roche), and normalized to the amounts of internal 
normalization control transcripts (18S rRNA). Results are expressed as relative mRNA level units 
referred to the average value obtained for the KRIT1
-/-
 (K
-/-
) samples, and represent the mean (± 
s.d.) of n=3 independent RT-qPCR experiments. ***P≤0.001 versus KRIT1-/- (K-/-) cells.  
B) Representative Western blot analysis. COX-2 levels in cell lysates were analyzed by Western 
blotting with an anti-COX-2 mAb and compared to the relative P-c-Jun and KRIT1 levels. Tubulin 
(-Tub) was used as loading control. 
Notice that KRIT1 loss-of-function reproduced in KRIT1
-/-
 MEF cells (K
-/-
) caused a significant up-
regulation of COX-2 expression at both mRNA and protein levels, which was completely rescued 
by the re-expression of KRIT1 (K9/6). It is also evident COX-2 protein levels are directly and 
inversely correlated with P-c-Jun and KRIT1 protein levels, respectively. 
C) Immunohistochemical analysis of paraffin-embedded human cerebral cavernous malformations 
with anti-COX-2 antibodies. Cavernous malformation tissue was collected from a CCM1 mutation 
carrier with familial disease at the time of surgical resection under an approved institutional review 
board protocol. Notice that many endothelial cells lining the lumen (l) of CCM vessels were 
positive for COX-2. 
 
Figure 9. Schematic model representing the inverse relathionship between KRIT1 and c-Jun 
expression levels and its putative functional significance. 
See text for detail. 
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